OncoHost, a technology company focused on precision medicine, announced on Monday that the Business Intelligence Group has named OncoHost as a winner in the 2026 BIG Innovation Awards in the Health category.
Additionally, OncoHost was selected as a Top 10 Innovator – Small Business, reflecting the company's leadership in developing clinically impactful technologies.
OncoHost was recognised for its PROphet platform, an AI-driven plasma-proteomics solution designed to help oncologists predict clinical benefit and therapy-related toxicity from a single pre-treatment blood test. Its first commercial offering, PROphetNSCLC, guides first-line immunotherapy decision-making in metastatic non-small cell lung cancer (NSCLC) by revealing host-response insights that extend beyond tumour-only biomarkers.
The BIG Innovation Awards are designed to honour organisations, products, and leaders transforming industries through applied innovation, intelligent platforms, and measurable real-world impact.
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China
INOVIO's INO-3107 Biologics License Application accepted by US FDA
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
GSK agrees US pricing framework to expand access to respiratory medicines
Century Health partnerss with Tessel Biosciences to advance early drug development in COPD
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema